Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$50.88M

FY 2025 · Annual

Investing Cash Flow

$36.23M

FY 2025 · Annual

Financing Cash Flow

$69.36M

FY 2025 · Annual

+33.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.71M)(13.88M)(31.48M)(35.48M)(69.38M)
Depreciation & Amortization36K09K39K64K
Deferred Income Tax00001.04M
Stock-Based Compensation4.21M4.02M3.28M3.1M6.26M
Change in Working Capital720K1.68M(392K)1.76M11.37M
Accounts Receivables00000
Inventory00000
Accounts Payables(294K)207K271K3.02M5.54M
Other Working Capital1.01M1.47M(663K)(1.26M)5.83M
Other Non-Cash Items61K0(131K)(158K)(237K)
Operating Cash Flow(16.68M)(8.19M)(28.71M)(30.75M)(50.88M)
Capital Expenditures00(88K)(37K)(116K)
Acquisitions (Net)00000
Purchases of Investments00(9.97M)(35.96M)0
Sales of Investments0010.1M036.35M
Other Investing Activities00000
Investing Cash Flow0047K(35.99M)36.23M
Debt Repayment00000
Common Stock Issued62K7.23M24.74M53M76.83M
Common Stock Repurchased000(1K)0
Dividends Paid00000
Other Financing Activities(106K)12K(44K)(1.14M)(7.47M)
Financing Cash Flow(44K)7.24M24.68M51.86M69.36M
Effect of Forex Changes00000
Net Change in Cash(16.72M)(944K)(3.98M)(14.88M)54.71M
Free Cash Flow(16.68M)(8.19M)(28.79M)(30.78M)(51M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$69.4M
+ D&A$64.0K
+ Stock-Based Comp$6.3M
+ Deferred Tax$1.0M
+ Working Capital$11.4M
- Other Non-Cash-$237.0K
= Operating Cash Flow-$50.9M
- Capex-$116.0K
= Free Cash Flow-$51.0M

Analysis

FY2025 free cash flow is -$51.0M. FCF conversion is 73.5% of net income. Operating cash flow was -$50.9M, with capex of -$116.0K. The largest bridge item is Working Capital at $11.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 14D9/ASC 14D9/A filingAug 21, 2026
SC TO-T/ASC TO-T/A filingAug 19, 2026
SC 14D9/ASC 14D9/A filingAug 19, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 13, 2026

Does FBRX generate free cash flow?

Forte Biosciences, Inc. (FBRX) generated -$51.00M of free cash flow in fiscal 2025.

How much operating cash flow does FBRX produce?

Operating cash flow was -$50.88M, before capital expenditures of $116,000.00.